Bremmer Felix, Schallenberg Simon, Jarry Hubertus, Küffer Stefan, Kaulfuss Silke, Burfeind Peter, Strauß Arne, Thelen Paul, Radzun Heinz Joachim, Ströbel Philipp, Honecker Friedemann, Behnes Carl Ludwig
Institute of Pathology, University of Göttingen, Göttingen, Germany.
Department of Endocrinology, University Medical Center Göttingen, Göttingen, Germany.
Oncotarget. 2015 Oct 20;6(32):33426-37. doi: 10.18632/oncotarget.5288.
Germ cell tumors (GCTs) are the most common malignancies in young men. Most patients with GCT can be cured with cisplatin-based combination chemotherapy, even in metastatic disease. In case of therapy resistance, prognosis is usually poor. We investigated the potential of N-cadherin inhibition as a therapeutic strategy. We analyzed the GCT cell lines NCCIT, NTERA-2, TCam-2, and the cisplatin-resistant sublines NCCIT-R and NTERA-2R. Effects of a blocking antibody or siRNA against N-cadherin on proliferation, migration, and invasion were investigated. Mouse xenografts of GCT cell lines were analyzed by immunohistochemistry for N-cadherin expression. All investigated GCT cell lines were found to express N-cadherin protein in vitro and in vivo. Downregulation of N-cadherin in vitro leads to a significant inhibition of proliferation, migration, and invasion. N-cadherin-downregulation leads to a significantly higher level of pERK. N-cadherin-inhibition resulted in significantly higher rates of apoptotic cells in caspase-3 staining. Expression of N-cadherin is preserved in cisplatin-resistant GCT cells, pointing to an important physiological role in cell survival. N-cadherin-downregulation results in a significant decrease of proliferation, migration, and invasion and stimulates apoptosis in cisplatin-naive and resistant GCT cell lines. Therefore, targeting N-cadherin may be a promising therapeutic approach, particularly in cisplatin-resistant, therapy refractory and metastatic GCT.
生殖细胞肿瘤(GCTs)是年轻男性中最常见的恶性肿瘤。大多数GCT患者即使患有转移性疾病,也可通过以顺铂为基础的联合化疗治愈。在治疗耐药的情况下,预后通常较差。我们研究了抑制N-钙黏蛋白作为一种治疗策略的潜力。我们分析了GCT细胞系NCCIT、NTERA-2、TCam-2以及顺铂耐药亚系NCCIT-R和NTERA-2R。研究了针对N-钙黏蛋白的阻断抗体或小干扰RNA对增殖、迁移和侵袭的影响。通过免疫组织化学分析GCT细胞系的小鼠异种移植瘤中N-钙黏蛋白的表达。结果发现,所有研究的GCT细胞系在体外和体内均表达N-钙黏蛋白。体外下调N-钙黏蛋白可显著抑制增殖、迁移和侵袭。N-钙黏蛋白下调导致pERK水平显著升高。抑制N-钙黏蛋白导致半胱天冬酶-3染色中凋亡细胞比例显著升高。顺铂耐药的GCT细胞中N-钙黏蛋白的表达得以保留,这表明其在细胞存活中具有重要的生理作用。下调N-钙黏蛋白可显著降低顺铂初治和耐药的GCT细胞系的增殖、迁移和侵袭,并刺激细胞凋亡。因此,靶向N-钙黏蛋白可能是一种有前景的治疗方法,特别是对于顺铂耐药、治疗难治性和转移性GCT。